Sarah Cannon Research Institute Adopts Veeva Systems' Clinical Platform for Unified Trial Management

Sarah Cannon Research Institute (SCRI), a leading oncology research organization, has announced a significant move to streamline its clinical trial operations by adopting Veeva Systems' clinical platform. This strategic decision aims to unify the institute's site management and contract research organizations (CRO) under a single, comprehensive system.

Standardizing Processes Across Research Sites

The adoption of Veeva's clinical platform is set to revolutionize SCRI's approach to managing clinical trials. By standardizing trial processes and information flow, the platform will provide clinical teams with a shared foundation, enabling more efficient collaboration and data sharing across research sites.

Jim Reilly, Vice President of R&D Strategy at Veeva, expressed enthusiasm about the partnership, stating, "We're excited to work closely with SCRI to drive innovation in oncology research. In a first-of-a-kind partnership, Veeva Clinical Platform will serve as SCRI's clinical trial foundation for its CRO and SMO. By standardizing operations on one platform, we can support SCRI in delivering faster and more cost-effective trials."

Expanding Reach and Partnerships

SCRI's extensive network, comprising over 200 locations across more than 20 states and involving 1,300 physicians, stands to benefit significantly from this technological upgrade. The standardization of operations is expected to enhance the institute's capacity to conduct large-scale, diverse clinical trials.

This move comes on the heels of SCRI's recent partnership with AbbVie, announced last month, which focuses on running diverse trials for the pharmaceutical giant's novel cancer candidates. The adoption of Veeva's platform is likely to bolster SCRI's ability to manage such high-profile collaborations effectively.